Literature DB >> 2834445

The human MHC-restricted cellular response to herpes simplex virus type 1 is mediated by CD4+, CD8- T cells and is restricted to the DR region of the MHC complex.

D S Schmid1.   

Abstract

The nature of the in vitro human cytotoxic T-cell responder population to HSV type 1 (HSV-1) was studied. In 5-day HSV-1-stimulated cultures that contained MHC-restricted activity, two phenotypically distinct populations of cells were present that were capable of lysing HSV-1-infected B cell lines in a 5-h 51Cr-release assay. The first was CD4+, CD8-, CD16- cell typical of class II-restricted T cells, whereas the other population bore a CD4-, CD8-, CD16+ NK-cell phenotype. Elimination of the NK cell fraction from bulk cultures by using anti-CD16 plus C frequently resulted in cell populations that killed in an Ag-specific, HLA-DR-restricted fashion. In some cases the anti-CD16-pretreated cultures retained a killing population that was unrestricted to MHC products. In no instance were any cytotoxic T cells that were restricted to class I Ag in evidence. Limiting dilution analysis of precursor frequency indicated that about 1 in 4000 to 1 in 8000 cells from peripheral blood are specific for HSV-1 in seropositive individuals. Comparisons of HLA class I-matched and HLA class II-matched targets with the autologous target by using limiting dilution analysis yielded results entirely consistent with those obtained in the bulk culture assay system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834445

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

Review 2.  Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.

Authors:  Emmanuel J Wiertz; Robert Devlin; Helen L Collins; Maaike E Ressing
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

3.  Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes.

Authors:  I Bourgault; A Gomez; E Gomard; J P Levy
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

Review 4.  The cellular immune response to nucleocapsid antigens in hepatitis B virus infection.

Authors:  M U Mondelli; F V Chisari; C Ferrari
Journal:  Springer Semin Immunopathol       Date:  1990

5.  Cytotoxic T cells against herpes simplex virus in Behçet's disease.

Authors:  K Hamzaoui; A Kahan; K Ayed; M Hamza
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

Review 6.  Experimental investigation of herpes simplex virus latency.

Authors:  E K Wagner; D C Bloom
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

7.  HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells.

Authors:  S Jacobson; R P Sekaly; C L Jacobson; H F McFarland; E O Long
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

8.  Proliferative T-cell response to glycoprotein B of the human herpes viruses: the influence of MHC and sequence of infection on the pattern of cross-reactivity.

Authors:  W L Chan; M L Tizard; L Faulkner
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

9.  Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein.

Authors:  R S van Binnendijk; J P Versteeg-van Oosten; M C Poelen; H F Brugghe; P Hoogerhout; A D Osterhaus; F G Uytdehaag
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  In vitro enhancement of natural killer cell activity against herpesvirus-infected targets in patients with acute lymphocytic leukemia.

Authors:  J R McKolanis; A H Ragab; D S Schmid
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.